Scopolamine api market

Q: Which is the leading form segment in the market?

Powder is the leading form segment in the market Read more

Scopolamine API Market, by Form (Powder and Liquid), by Purity (≥99% and ≥ 98%), by Scale of Production (Industrial scale, Pilot scale, and Laboratory scale), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Oct 2022
CMI5270
202 Pages
Excel & Pdf
Pharmaceutical

Summary

Scopolamine, also known as hyoscine, or devil's breath, is a natural or synthetically produced tropane alkaloid and anticholinergic drug that is formally used as a medication for treating motion sickness and postoperative nausea and vomiting. It has applications in prevention of nausea, vomiting, and dizziness associated with motion sickness and recovery from anesthesia and surgery. Scopolamine may also be used to treat certain stomach or intestinal problems, such as spastic muscle states, diverticulitis, irritable bowel syndrome, Parkinson-like conditions etc.

The global scopolamine API market is estimated to be valued at US$ 292.96 million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030).

Figure 1.Global Scopolamine API Market Share (%), by Form, 2022

Increasing number of surgeries globally is expected to drive growth of the scopolamine API market

Scopolamine is used as a medication for treating postoperative nausea and vomiting. Thus the rising number of surgeries is expected to drive the market growth over the forecast period. For instance, according to the news provided by the Asiri Central’s Brain and Spine Centre, in March 2020, Colombo marked a significant milestone recently of having performed 10,000 neurosurgical procedures since it was established in June 2010. The hospital has treated an average of 1,000 patients per year over the past five years

Figure 2.Global Scopolamine API Market Share (%), by Purity, 2022

Increasing product launch by key players in the market is expected to drive the market growth during the forecast period.

The key players in the market are adopting organic growth strategies such as product launch, which is expected to drive the market growth over the forecast period. For instance, in October 2019, Perrigo Company plc, an over-the-counter consumer goods and specialty pharmaceutical company, announced the relaunch of the AB rated generic equivalent of Transderm Scop (scopolamine 1.5 mg), used to treat the symptoms of nausea or vomiting.

Scopolamine API Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 292.96 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.3%	2030 Value Projection:	US$ 442.72 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Form: Powder, Liquid By Purity: ≥99%, ≥ 98% By Scale of Production: Industrial scale, Pilot scale, Laboratory scale
Companies covered:	Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP
Growth Drivers:	Increasing number of surgeries globally Increasing product launch by key players in the market
Restraints & Challenges:	Side effects associated with scopolamine and misuse of scopolamine

Global Scopolamine API Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of products from one place to another

The COVID-19 pandemic had a negative effect on the global scopolamine API market due to the decline in surgical operations for chronic conditions brought on by the ongoing COVID-19 pandemic. According to an article published by the Wolters Kluwer Health,Inc. an organization providing professional information, software solutions, and services for the health, tax & accounting, governance, risk & compliance, and legal & regulatory sectors, the COVID-19 pandemic has led to significant disruption in the provision of surgical services, with an estimated cancellation of 28 million operations worldwide during the first wave of covid alone.

Global Scopolamine API Market: Restraint

The major factor that hinder growth of the global scopolamine API market include side effects associated with scopolamine and misuse of scopolamine. Scopolamine may cause side effects such as dry mouth, sleepiness, urinary retention, agitation, dilated pupils, sore throat, drowsiness, dizziness, etc. Some side effects can be serious which include rash, redness, difficulty speaking, seizure, painful or difficulty urinating, stomach pain, nausea, vomiting, etc.

Key Players

Major players operating in the global scopolamine API market include Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP

Table of Content

Table of Contents

*Browse 69 market data tables and 31 figures on "Global Scopolamine API Market” - forecast to 2030

Segmentation

Detailed Segmentation:

Global Scopolamine API Market, By Form:
- Powder
- Liquid
Global Scopolamine API Market, By Purity:
- ≥99%
- ≥ 98%
Global Scopolamine API Market, By Scale of Production:
- Industrial scale
- Pilot scale
- Laboratory scale
Global Scopolamine API Market, By Region:
- North America
  - By Form
    - Powder
    - Liquid
  - By Purity
    - ≥99%
    - ≥ 98%
  - By Scale of Production
    - Industrial scale
    - Pilot scale
    - Laboratory scale
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Form
    - Powder
    - Liquid
  - By Purity
    - ≥99%
    - ≥ 98%
  - By Scale of Production
    - Industrial scale
    - Pilot scale
    - Laboratory scale
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Form
    - Powder
    - Liquid
  - By Purity
    - ≥99%
    - ≥ 98%
  - By Scale of Production
    - Industrial scale
    - Pilot scale
    - Laboratory scale
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Form
    - Powder
    - Liquid
  - By Purity
    - ≥99%
    - ≥ 98%
  - By Scale of Production
    - Industrial scale
    - Pilot scale
    - Laboratory scale
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Form
    - Powder
    - Liquid
  - By Purity
    - ≥99%
    - ≥ 98%
  - By Scale of Production
    - Industrial scale
    - Pilot scale
    - Laboratory scale
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Form
    - Powder
    - Liquid
  - By Purity
    - ≥99%
    - ≥ 98%
  - By Scale of Production
    - Industrial scale
    - Pilot scale
    - Laboratory scale
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global scopolamine API market during the forecast period (2022-2030)?

The global scopolamine API market size is estimated to be valued at US$ 292.96 million in 2022 and is expected to exhibit a CAGR of 5.3% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing number of surgeries globally and increasing product launch by key players in the market are expected to drive the market growth.

Which is the leading form segment in the market?

Powder is the leading form segment in the market

What are the key factors hampering growth of the market?

The major factor hampering growth of the market include side effects associated with scopolamine and misuse of scopolamine.

Which are the major players operating in the market?

Major players operating in the market include Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP